Business
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company
About this update from Arcutis Biotherapeutics, Inc.
[{"type":"text","content":"WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the promotion of Mas Matsuda, JD, currently senior vice president and general counsel, to executive vice president, chief legal officer, and corporate secretary. Mr. Matsuda will continue to lead the Company’s legal, compliance, and governance strategy in support of the continued growth of the Company, commercialization of the ZORYVE® (roflumilast) portfolio, and protection of the Company’s intellectual property, as well as any corporate transactions. “I am thrilled to announce Mas’ promotion,” said Frank Watanabe, president and chief executive officer of Arcutis. “Since joining Arcutis, Mas has been a trusted adviser and an instrumental leader, strengthening our legal and compliance foundation while supporting the successful development and growth of ZORYVE. As we highlighted in our recent fourth quarter and full-year results, Arcutis is entering an exciting next phase of growth. Mas’ strategic judgment, deep expertise, and steady leadership will be critical as we continue to expand our commercial presence and advance our portfolio.” Mr. Matsuda joined Arcutis in January 2022 as general counsel and corporate secretary, leading legal and compliance strategy and serving as secretary to the Board of Directors. He has helped guide the Company through a period of significant commercial growth, including six FDA approvals of the Company’s advanced targeted topical, ZORYVE, while building and scaling the Company’s legal, compliance, and governance framework. Prior to Arcutis, Mr. Matsuda served as senior vice president, general counsel, chief compliance officer, and corporate secretary at Halozyme Therapeutics, Inc. and previously held numerous legal positions including vice president, law, global commercial operations at Amgen. “Over the past four years, Arcutis has evolved into a leader in medical dermatology with a successful ZORYVE franchise and an advancing pipeline,” said Mas Matsuda, JD. “I am proud to continue contributing to the Company’s momentum and look forward to working alongside our leadership team as we enter the next phase of growth, delivering meaningful innovation for individuals suff...